However, in terms of TG, AP severity, and comorbidities, there was no significant difference between the HLAP patients with APOA5 pathogenic mutations and other HLAP patients without APOA5 pathogenic mutations (detailed in Table 3). The gene discussed is HLA-P; the disease is alkaline phosphatase measurement.